CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
The new online Learning Center with new content can still be found under the “Training” folder on ...
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...